Developing a one-time gene therapy to suppress HIV replication.
Official title: Non-viral gene therapy with eCD4-Ig
Funded at Emmune, INC · NIH-11195805 · Data updated 2026-11-12
This study is testing a new type of gene therapy that uses a special protein to help keep HIV under control with just one shot in the muscle, so people living with HIV might not need to take daily medications anymore.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emmune, INC NIH-funded |
| Lab location | 1 site (Juno Beach, UNITED STATES) |
| Project start | June 17, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $919,501 |
| NIH project number | 1R56AI189343-01 |
| Project ID | NIH-11195805 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are seeking a more permanent treatment option.
✕Less likely to help
Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
What this research studies
This research focuses on creating a non-viral gene therapy using a therapeutic protein called eCD4-Ig, which aims to provide long-lasting suppression of HIV after a single intramuscular injection. The therapy is designed to counteract the virus's ability to escape neutralizing antibodies, which is a significant challenge in treating HIV. By enhancing the efficiency of gene transfer into skeletal muscle, the researchers hope to maintain effective levels of eCD4-Ig in the body for a lifetime. This innovative approach could potentially eliminate the need for ongoing treatments for HIV.
Why it matters
Potential benefit: If successful, this research could lead to a long-term solution for managing HIV, significantly improving the quality of life for patients.
How similar studies have gone: While gene therapy for HIV is an emerging field, this specific approach using eCD4-Ig is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Emmune, INC
Juno Beach, United States Active
Researchers
- Principal investigator: Quinlan, Brian D — Emmune, INC
- Study coordinator: Quinlan, Brian D
Related research
Other NIH-funded projects on the same topics.
-
Non-viral gene therapy to treat and prevent atherosclerosis (for patients)
A small biotechnology study is testing a non-viral DNA delivery method using lipid nanoparticles to help prevent and treat atherosclerosis in adults.
-
Making eCD4-Ig, a long‑acting HIV medicine
Developing ways to manufacture eCD4-Ig, a long‑lasting antibody‑like medicine that could help people living with or at risk for HIV.
-
Long-acting eCD4-Ig therapy for HIV prevention and treatment
A FastTrack SBIR grant funds early non-human and IND-enabling tests to develop a long-acting eCD4-Ig protein that could be given every three months to help prevent or treat HIV.
-
Developing a long-acting treatment for HIV
This study is working on a new treatment for HIV that uses a special protein to help your body fight the virus, and it aims to make it easy to take with just a shot every three months.
-
Modified COVID-19 booster focused on the virus's receptor-binding domain
Testing a new COVID-19 booster that uses a modified piece of the virus's spike protein to steer immune protection toward parts that neutralize variants.
-
Developing targeted vaccines for COVID-19 variants
This study is testing a new type of booster vaccine designed to help people who have already been vaccinated against COVID-19 by making it better at fighting off different variants of the virus.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.